Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Oil Prices Surge Amid U.S.-Iran Tensions and Strait of Hormuz Disruptions 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
The four types of dementia most people don’t know exist 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
South Korea Economy Rebounds on Semiconductor Export Surge Amid Middle East Risks 
Energy Price Spike Won't Trigger Lasting Inflation, Analysts Say 
South Korea’s JW Pharmaceutical has received a patent in Russia for a hair loss treatment currently under development, marking the first time that its candidate drug has been patented overseas.
The pharmaceutical firm received a patent for JW0061, its Wnt-targeted hair loss treatment, from Russia's Federal Service for Intellectual Property.
The patent covers a new heterocyclic inducer of the Wnt signaling pathway, including its base or isomer, and compositions containing it as an active ingredient.
JW has also submitted patent applications in more than ten nations, including the US, EU, Japan, and China.
JW0061 exhibits a novel method of action by directly binding to the GFRA1 protein in human hair dermal papilla cells, activating the Wnt signaling pathway. This is the first instance of a low-molecular-weight medication that describes the mechanism of hair growth that has been documented.
JW is now evaluating non-clinical toxicity in accordance with good laboratory practice with the intention of initiating clinical trials for JW0061 in the first half of 2024. Additionally, it collaborates on research projects with eminent dermatologists in the US.
JW plans to develop JW0061 as a new innovative drug that supplements or replaces existing hair loss treatments.
